The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
The company has operations in North America, Asia, and Europe,
It is the world’s first DNA-based Covid vaccine
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
Equity raise to finance growth and investments in the biological space
Since its inception, the company has either acquired or taken a majority stake in five companies
Subscribe To Our Newsletter & Stay Updated
